U.S. Stocks Move: Merck (MRK.US) and Moderna (MRNA.US) Shares Surge as Personalized mRNA Cancer Vaccine Succeeds in Phase III Trial

智通财经APP has learned that on Wednesday, Merck (MRK.US) rose nearly 10% to $148.44. Moderna (MRNA.US) surged over 113% to $134.51. According to reports, Moderna and Merck announced today that their jointly developed personalized mRNA cancer vaccine has achieved positive results in a large-scale Phase III clinical trial, marking the first successful Phase III trial of mRNA technology in cancer treatment and representing a major breakthrough for personalized immunotherapy in cancer treatment history.